Enzalutamide, a potent oral androgen receptor inhibitor, improves survival in men with metastatic castration-resistant prostate cancer (CRPC) before and after chemotherapy. Bicalutamide, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results